Skip to content

Nēsos receives FDA Breakthrough Device Designation for its disease-modifying digital therapeutic for Rheumatoid Arthritis Nēsos, the company developing disease-modifying digital therapeutics for inflammation-mediated disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its digital therapeutic for patients with rheumatoid arthritis (RA) who have had an inadequate response…

Read More

A new crop of medical devices are trying to hack the vagus nerve to treat disease

Read More